Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Luz Elena Núñez"'
Autor:
Aniello Federico, Tamara Steinfass, Lionel Larribère, Daniel Novak, Francisco Morís, Luz-Elena Núñez, Viktor Umansky, Jochen Utikal
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss , Pp 83-99 (2020)
Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of
Externí odkaz:
https://doaj.org/article/99cbd00853c94ab28a3020afd9be2b9a
Autor:
Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, Gabriel Bretones, Ángel R. Payer, Ana P. González-Rodríguez, Esther González-García, Jhudit Pérez-Escuredo, Mónica Villa-Álvarez, Luz-Elena Núñez, Francisco Morís, Segundo Gonzalez, Alejandro López-Soto
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
B-cell receptor (BCR)-dependent signaling is central for leukemia B-cell homeostasis, as underscored by the promising clinical results obtained in patients with chronic lymphocytic leukemia (CLL) treated with novel agents targeting components of this
Externí odkaz:
https://doaj.org/article/c9308b239ec243ad9b6907c1bcabb68e
Autor:
Francisco Morís, Vanesa Martín, Carmen Rodríguez, Elisa Luño, Ana M. Sanchez-Sanchez, Nicolás Ríos-Lombardía, Jhudit Pérez-Escuredo, Maria Ana Hermosilla, Patricia Oro, Luz-Elena Núñez, Isaac Antolín, Paula Costales, Noelia Puente-Moncada
Kaplan-Meier plots
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5822a61c927847c3eca709190eb9d9e3
https://doi.org/10.1158/1535-7163.22505658
https://doi.org/10.1158/1535-7163.22505658
Autor:
Francisco Morís, Vanesa Martín, Carmen Rodríguez, Elisa Luño, Ana M. Sanchez-Sanchez, Nicolás Ríos-Lombardía, Jhudit Pérez-Escuredo, Maria Ana Hermosilla, Patricia Oro, Luz-Elena Núñez, Isaac Antolín, Paula Costales, Noelia Puente-Moncada
Internal tandem duplication (ITD) or tyrosine kinase domain mutations of FLT3 is the most frequent genetic alteration in acute myelogenous leukemia (AML) and are associated with poor disease outcome. Despite considerable efforts to develop single-tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::343751a2778aa714895c1b53ec277fa1
https://doi.org/10.1158/1535-7163.c.6538146.v1
https://doi.org/10.1158/1535-7163.c.6538146.v1
Autor:
Patrick J. Grohar, Francisco Morís, Lee J. Helman, Javier González-Sabín, Luz-Elena Núñez, Mary E. Winn, Zachary B. Madaj, Lisa Turner, Malcolm Smith, Min Kang, Stephen L. Lessnick, Savita Sankar, Min He, Girma M. Woldemichael, Meti Gebregiorgis, Laura Segars, Susan Kitchen-Goosen, Christopher G. Kidd, Nichole Maloney, Christy L. Osgood
Purpose: The goal of this study was to identify second-generation mithramycin analogues that better target the EWS-FLI1 transcription factor for Ewing sarcoma. We previously established mithramycin as an EWS-FLI1 inhibitor, but the compound's toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d0749f76a543249a5b3ef28f63aea13
https://doi.org/10.1158/1078-0432.c.6523083.v1
https://doi.org/10.1158/1078-0432.c.6523083.v1
Autor:
Patrick J. Grohar, Francisco Morís, Lee J. Helman, Javier González-Sabín, Luz-Elena Núñez, Mary E. Winn, Zachary B. Madaj, Lisa Turner, Malcolm Smith, Min Kang, Stephen L. Lessnick, Savita Sankar, Min He, Girma M. Woldemichael, Meti Gebregiorgis, Laura Segars, Susan Kitchen-Goosen, Christopher G. Kidd, Nichole Maloney, Christy L. Osgood
Table S1, PCR primers used in gene signature panel. Table S2, Evidence for selection of each gene as an EWS-FLI1 target. S3A Mean fold change in expression of NR0B1 as a function of GAPDH (2Î"Î"CT) following treatment with MMA or EC-8105. Data is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41af203bf3e40e5edb0bf0c619f46fdf
https://doi.org/10.1158/1078-0432.22455681
https://doi.org/10.1158/1078-0432.22455681
Autor:
Lionel Larribère, Aniello Federico, Luz Elena Núñez, Viktor Umansky, Daniel Novak, Tamara Steinfass, Francisco Morís, Jochen Utikal
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss, Pp 83-99 (2020)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f06c23076924620442bf0d5f2e788b3d
https://doi.org/10.1016/j.omto.2020.06.001
https://doi.org/10.1016/j.omto.2020.06.001
Autor:
Azahara Fernández-Guizán, Alejandro López-Soto, Andrea Acebes-Huerta, Leticia Huergo-Zapico, Mónica Villa-Álvarez, Luz-Elena Núñez, Francisco Morís, Segundo Gonzalez
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0140786 (2015)
Demycarosyl-3D-ß-D-digitoxosyl-mithramycin SK (DIG-MSK) is a recently isolated analogue of mithramycin A (MTA) that showed differences with MTA in the DNA binding strength and selectivity. These differences correlated with a better therapeutic index
Externí odkaz:
https://doaj.org/article/83710cf680c6406cb141edd759977f02
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104687 (2014)
Ovarian cancer has a poor prognosis due to intrinsic or acquired resistance to some cytotoxic drugs, raising the interest in new DNA-binding agents such as mithramycin analogues as potential chemotherapeutic agents in gynecological cancer. Using a ge
Externí odkaz:
https://doaj.org/article/91348b9354184d728260e406079e53eb
Autor:
Jesus Cortes, Wolfgang Wohlleben, Mirna Rodriguez, Carmen Méndez, Bernd Jandeleit, Michał Krawiec, Michael Eitel, Marcin Wolański, Luz Elena Núñez, Alma Botas, Wolf-Nicolas Fischer, Francisco Morís, Evi Stegmann, Anina Buchmann, Jolanta Zakrzewska-Czerwińska, Paul N. Schwarz, Pierre Koch, Bertolt Gust, Paula Costales, Harald Gross
Publikováno v:
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
Universidad de las Islas Baleares
Angewandte Chemie (International Ed. in English)
RUO: Repositorio Institucional de la Universidad de Oviedo
Universidad de Oviedo (UNIOVI)
RUO. Repositorio Institucional de la Universidad de Oviedo
Universidad de las Islas Baleares
Angewandte Chemie (International Ed. in English)
RUO: Repositorio Institucional de la Universidad de Oviedo
Universidad de Oviedo (UNIOVI)
Brasilicardin A (1) consists of an unusual anti/syn/anti‐perhydrophenanthrene skeleton with a carbohydrate side chain and an amino acid moiety. It exhibits potent immunosuppressive activity, yet its mode of action differs from standard drugs that a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1944b1a37083ecd0e9e666bc761864bc
http://hdl.handle.net/10651/60008
http://hdl.handle.net/10651/60008